Researchers reported positive results from a unique cell treatment experiment for individuals with diabetes.

The NEPHSTROM clinical trial is commencing to investigate the potential of new cell therapy for treating type 2 diabetic patients with increased risk of kidney damage despite obtaining the best medical care. 

The findings of the NEPHSTROM clinical trial were presented in November At the Kidney Week meeting of the American Society of Nephrology in Orlando, Florida,. It demonstrated that a single intravenous dose of ORBCEL-M, given to carefully chosen patients with deteriorating kidney disease brought on by diabetes, was safe and improved the preservation of kidney function than a placebo. ORBCEL-M aims to reduce systemic inflammation and enhance kidney function to prevent patients from needing dialysis or a kidney transplant. Following the administration of ORBCEL-M, trial participants were regularly monitored for 18 months.

ORBCEL-M cell treatment has been discovered and developed by Orbsen Therapeutics Ltd., a spinout firm from the University of Galway, in Galway, using mesenchymal stromal cells (MSC) prepared from healthy bone marrow.

Researchers reported that the safety profile and early efficacy signs in diabetic kidney disease( DKD) patients presented by the NEPHSTROM trial, were encouraging and they were looking forward for collaboration of University of Galway and NEPHSTROM partners to carry out the Phase 3 efficacy trials and a market approval.

(Source: https://www.hindustantimes.com/lifestyle/health/cell-therapy-helps-to-reduce-kidney-damage-from-type-2-diabetes-study-101671591962290.html)